1. Home
  2. UTF vs GPCR Comparison

UTF vs GPCR Comparison

Compare UTF & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Infrastructure Fund Inc

UTF

Cohen & Steers Infrastructure Fund Inc

HOLD

Current Price

$27.00

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$44.81

Market Cap

2.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTF
GPCR
Founded
N/A
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.8B
IPO Year
2004
2023

Fundamental Metrics

Financial Performance
Metric
UTF
GPCR
Price
$27.00
$44.81
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$103.17
AVG Volume (30 Days)
290.5K
701.2K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.42
$15.80
52 Week High
$27.65
$94.90

Technical Indicators

Market Signals
Indicator
UTF
GPCR
Relative Strength Index (RSI) 48.91 61.56
Support Level $26.54 $42.72
Resistance Level $27.23 $57.23
Average True Range (ATR) 0.33 2.20
MACD -0.00 0.91
Stochastic Oscillator 36.44 74.71

Price Performance

Historical Comparison
UTF
GPCR

About UTF Cohen & Steers Infrastructure Fund Inc

Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: